Daiichi Sankyo Co Ltd 2012 SR
The report highlights Daiichi Sankyo's progress in its Second Mid-term Business Management Plan (FY2010-2012), focusing on its vision to become a Global Pharma Innovator. Key achievements include the launch of innovative drugs like Memary and LIXIANA in Japan, and the malaria treatment Synriam in India. The company joined the UN Global Compact in April 2012 and revised its Corporate Conduct Charter to align with global standards. Environmental efforts resulted in a 5.3% reduction in global CO2 emissions, while social initiatives expanded through mobile healthcare clinics in India, Cameroon, and Tanzania.
Company: Daiichi Sankyo Co Ltd
Sector: Manufacturing
Country: Japan
Year: 2012
Type: SR
Pages: 82
Back to company
Daiichi Sankyo Co Ltd
Corporate Social Responsibility Report
The report highlights Daiichi Sankyo's progress in its Second Mid-term Business Management Plan (FY2010-2012), focusing on its vision to become a Global Pharma Innovator. Key achievements include the launch of innovative drugs like Memary and LIXIANA in Japan, and the malaria treatment Synriam in India. The company joined the UN Global Compact in April 2012 and revised its Corporate Conduct Charter to align with global standards. Environmental efforts resulted in a 5.3% reduction in global CO2 emissions, while social initiatives expanded through mobile healthcare clinics in India, Cameroon, and Tanzania.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2012
Reporting Period
Apr 1, 2011 - Mar 31, 2012
Fiscal Year
2011
Published
Aug 1, 2012
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Total Waste
Women on Board
Women in Management
Employees